Investors Tire of A...
Health Care: Drugs
Impax Laboratories Inc. (IPXL: NASDAQ)
$21.75 -0.23 | -1.05%
02/09/12 - 03:59 PM ET
2.64M / 542.40K
Vol / Avg. Vol:20.93 / 21.98
Open / Prev. Close:20.30 - 22.11
Today's Range:14.46 - 28.75
52 Wk Range:8.97%
Performance YTD:TheStreet Rating:
Portfolios with IPXL
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- Contributor8 Pharma Stocks to Watch
- Contributor5 Bargain Biotech Stocks
- UserAberian System, MEDICAL stocks
- UserDavid Maxwell Portfolio 1
- UserPART 2 JPMorgan 28th Annual...
- ContributorBarron's Insider Purchases ...
- UserPART 5 JPMorgan 26th Annual...
- ProVanguard Capital Value - VCVLX
Latest IPXL Headlines from TheStreet
- Impax Rises On Unusually High Volume (IPXL) 02.02.12 | 04:02 pm
- 8 Stocks Rising on Huge Volume 02.01.12 | 02:02 pm
- UBS: 8 Pharma Stocks to Watch 01.20.12 | 12:01 pm
- Impax Laboratories Inc. Stock Upgraded (IPXL) 01.19.12 | 06:01 am
- Impax Laboratories Inc. Stock Downgraded (IPXL) 08.16.11 | 07:08 am
- Impax Stock Gaps Up On Today's Open (IPXL) 08.15.11 | 09:08 am
- Impax Reaches New 52-Week High (IPXL) 05.05.11 | 11:05 am
- Impax Stock Hits New 52-Week High (IPXL) 04.04.11 | 11:04 am
- Impax Stock Hits New 52-Week High (IPXL) 03.15.11 | 10:03 am
- Impax Labs, Subaye: After-Hours Trading 03.14.11 | 06:03 pm
Press Releases for IPXL
- Impax Laboratories Provides Update On Status Of Warning Letter Resolution For Its Hayward Facility - Business Wire 02.09.12 | 07:02 am
- Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights To Zomig® (zolmitriptan) From AstraZeneca - Business Wire 02.01.12 | 08:02 am
- Impax Laboratories Schedules Conference Call And Webcast For Fourth Quarter And Full Year 2011 Financial Results - Business Wire 01.26.12 | 09:01 am
- Impax Laboratories To Present At The J.P. Morgan Healthcare Conference - Business Wire 01.04.12 | 09:01 am
- Impax Pharmaceuticals Submits New Drug Application For IPX066 In Parkinson’s Disease - Business Wire 12.21.11 | 08:12 am
- Impax Pharmaceuticals Initiates Phase IIb Trial Of IPX159 In Restless Legs Syndrome - Business Wire 12.19.11 | 11:12 am
- Impax Laboratories To Present At The Piper Jaffray 23rd Annual Healthcare Conference - Business Wire 11.23.11 | 11:11 am
- Impax Laboratories Confirms Patent Challenge Relating To Generic FENTORA® - Business Wire 11.21.11 | 08:11 am
- Impax Laboratories To Present At The Credit Suisse 2011 Healthcare Conference - Business Wire 11.07.11 | 09:11 am
- Impax Laboratories Reports Third Quarter 2011 Financial Results - Business Wire 11.01.11 | 07:11 am
Partner Headlines for IPXL
- Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue - Benzinga 10.21.11 | 04:10 pm
- Relief for Warner Chilcott - Analyst Blog - Zacks 09.30.11 | 02:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
- US Indexes Remain Higher Into Session's Half Despite Weak Manufacturing Data; Commodities Higher - NASDAQ 08.15.11 | 04:08 pm
- Mid-Day Update: Stocks Green Despite Weak Manufacturing Data; Commodities Rise - NASDAQ 08.15.11 | 04:08 pm
- 10 High Quality Stocks to Consider - Seeking Alpha 06.28.11 | 08:06 am
- Top Percentage Gainers and Losers as of 2pm 06/08/11 - Benzinga 06.08.11 | 02:06 pm
- Daily State of the Markets: No Hint, No Bounce - Seeking Alpha 06.08.11 | 09:06 am
- Contrarian Ideas: 6 Undervalued Stocks With Extremely Bearish Put/Call Ratios - Seeking Alpha 06.08.11 | 09:06 am
- 5 Stocks to Watch Today - Seeking Alpha 03.15.11 | 08:03 am
